

UnitedHealthcare Oxford **Policy Update Bulletin: December 2021**

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

Take Note

Annual CDT®, CPT®, and HCPCS Code Updates

Beginning Jan. 1, 2022, all applicable Clinical and Administrative Policies will be updated to reflect the 2022 Current Dental Terminology (CDT°), Current Procedural Terminology (CPT°), and Healthcare Common Procedure Coding System (HCPCS) code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- American Dental Association[®]. Current Dental Terminology: CDT[®]
- American Medical Association. Current Procedural Terminology: CPT[®]
- Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System: HCPCS Level II

Complete details on impacted policies and corresponding code edits will be provided in the January 2022 edition of the Oxford Policy Update Bulletin.

Oxford Reimbursement Policies Relocated

Beginning Jan. 1, 2022, Oxford will utilize the UnitedHealthcare Commercial Reimbursement Policies on UHCprovider.com; we will no longer maintain Oxford-specific Reimbursement Policy versions. Updates to the Reimbursement Policies will now only be announced in the *UnitedHealthcare Commercial Reimbursement Policy Update Bulletin*.

Clinical Policy Updates

Policy Title	Status	Effective Date
Airway Clearance Devices	Revised	Jan. 1, 2022
Apheresis	Revised	Jan. 1, 2022
Cosmetic and Reconstructive Procedures	Revised	Jan. 1, 2022
Drug Coverage Criteria: New and Therapeutic Equivalent Medications	Revised	Jan. 1, 2022
Drug Coverage Guidelines Amitiza (Lubiprostone) Brukinsa (Zanubrutini) Bylvay (Odevixibat) Copaxone (Brand Only) (Glatiramer Acetate) Devices Dextroamphetamine 15 mg, 20 mg, 30 mg (Generic Zenzedi) Drizalma Sprinkle (Duloxetine) Exservan (Riluzole) Extavia (Interferon B-1b) Farxiga (Dapagliflozin) Fintepla (Fenfluramine) Flolipid (Simvastatin Suspension) Glyxambi (Empagliflozin/Linagliptin) Intrarosa (Prasterone)	Revised	Jan. 1, 2022

olicy Title	Status	Effective Date
Invokamet (Canagliflozin/Metformin)		
Invokamet XR (Canaglifloxin/Metformin Extended-Release)		
Invokana (Canagliflozin)		
Jardiance (Empagliflozin)		
Katerzia (Amlodipine Benzoate)		
Lubiprostone (Generic Amitiza)		
Lymepak (Doxycycline Hyclate)		
Nexviazyme [™] (Avalglucosidase Alfa-Ngpt)		
Odomzo (Sonidegib)		
Ponvory (Ponesimod)		
Qtern (Dapagliflozin/Saxagliptin)		
Rebif (Interferon Beta-1a)		
Renvela (Sevelamer Carbonate) Powder for Suspension		
Ryplazim (Plasminogen, Human-Tvmh)		
Sandostatin (Octreotide Acetate)		
Sandostatin (Brand Only) (Octreotide Acetate)		
Saphnelo (Anifrolumab-Fnia)		
Scemblix (Asciminib)		
Segluromet (Ertugliflozin/Metformin Hcl)		
Sertraline Capsules 150 mg, 200 mg (Generic Zoloft)		
Skytrofa (Lonapegsomatropin-Tcgd) Sprycel (Dasatinib)		
Steglatro (Ertugliflozin)		
Steglujan (Ertugliflozin/Sitagliptin)		
Tasigna (Nilotinib)		
Tavneos (Avacopan)		
Tecfidera (Dimethyl Fumarate) (Brand)		
Temodar (Temozolomide)		
Thalitone 15 mg (Chlorthalidone USP)		
Tibsovo (Ivosidenib)		
Turalio (Pexidartinib)		
Tykerb (Brand Only) (Lapatinib)		
Tykerb (Generic Only) (Lapatinib)		
Tyrvaya (Varenicline Solution)		
Valchlor Gel (Mechlorethamine)		
Vimpat (Lacosamide): Tablet		
Vraylar (Cariprazine)		
Vumerity (Diroximel Fumarate)		
Welireg (Belzutifan)		
Xalkori (Crizotinib)		
Xatmep (Methotrexate)		
Xigduo XR (Dapagliflozin and Metformin Hcl)		
Zolinza (Vorinostat)		
Zykadia (Ceritinib)		
ectrical and Ultrasound Bone Growth Stimulators	Revised	Jan. 1, 2022
renity® (Romosozumab-Aqqg)	Revised	Jan. 1, 2022
me Disease	Revised	Jan. 1, 2022
mnibus Codes	Revised	Jan. 1, 2022
	Revised	
utpatient Surgical Procedures - Site of Service		Feb. 1, 2022
ercutaneous Vertebroplasty and Kyphoplasty	Updated	Dec. 1, 2021
eventive Care Services	Revised	Jan. 1, 2022
olotherapy and Platelet Rich Plasma Therapies	Updated	Jan. 1, 2022
rosthetic Devices, Wigs, Specialized, Microprocessor or Myoelectric Limbs	Updated	Jan. 1, 2022

Policy Title	Status	Effective Date
Ryplazim® (Plasminogen, Human-Tvmh)	Revised	Jan. 1, 2022
Sandostatin LAR® Depot (Octreotide Acetate)	Updated	Dec. 1, 2021
Skin and Soft Tissue Substitutes	Revised	Jan. 1, 2022
Visual Information Processing Evaluation and Orthoptic and Vision Therapy	Revised	Jan. 1, 2022
Vyepti [™] (Eptinezumab-Jjmr)	Revised	Jan. 1, 2022
Xolair® (Omalizumab)	Revised	Jan. 1, 2022

Administrative Policy Updates

Policy Title	Status	Effective Date
Prior Authorization Exemptions for Outpatient Services	Revised	Jan. 1, 2022

Reimbursement Policy Updates

Policy Title	Status	Effective Date
Discontinued Procedure (CES)	Updated	Dec. 1, 2021

General Information

The inclusion of a health service (e.g., test, drug, device or procedure) in this bulletin indicates only that UnitedHealthcare Oxford® is adopting a new policy and/or updated, revised, replaced or retired an existing policy; it does not imply that UnitedHealthcare Oxford® provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare Oxford® reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare Oxford® respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding UnitedHealthcare Oxford® Clinical, Administrative, and Reimbursement Policy updates. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare Oxford® follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Oxford® Medical and Administrative Policies is available at OxfordHealth.com > Providers > Tools & Resources > Medical Information > Medical and Administrative Policies or at UHCprovider.com > Policies and Protocols > Commercial Policies > UnitedHealthcare Oxford Clinical, Administrative and Reimbursement Policies. Refer to the back of the member's health care ID card for the applicable website.